A Study to Determine the Safety and Efficacy of Atezolizumab in Patients with Urothelial Carcinoma (bladder cancer) after Surgery

What we are studying

The purpose of this study is to compare the effects, good or bad, of atezolizumab versus observation (not receiving any treatment) on you and your bladder cancer to find out which is better. In this study, you will get either atezolizumab or no treatment. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of bladder cancer. Atezolizumab is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the programmed death-ligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in regulating the body’s natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD L1 pathway, atezolizumab may help your immune system to stop or reverse the growth of tumors. Your study doctor will give you atezolizumab in the hospital.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • PLACEHOLDER

What is involved

  • PLACEHOLDER

Compensation

None

Contact Information

Study Coordinator
Patricia Smith, RN
Email
336-713-4416
Phone
psmith@wakehealth.edu
Principal Investigator
Michael Moses Goodman, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.